Compass Therapeutics (CMPX) Equity Ratio (2023 - 2025)
Compass Therapeutics (CMPX) has disclosed Equity Ratio for 3 consecutive years, with 0.9 as the latest value for Q4 2025.
- Quarterly Equity Ratio changed 0.47% to 0.9 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.9 through Dec 2025, changed 0.47% year-over-year, with the annual reading at 0.9 for FY2025, 0.47% changed from the prior year.
- Equity Ratio hit 0.9 in Q4 2025 for Compass Therapeutics, down from 0.91 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.97 in Q1 2024 to a low of 0.8 in Q2 2025.
- Historically, Equity Ratio has averaged 0.91 across 3 years, with a median of 0.93 in 2023.
- Biggest five-year swings in Equity Ratio: rose 4.54% in 2024 and later dropped 14.93% in 2025.
- Year by year, Equity Ratio stood at 0.95 in 2023, then decreased by 5.8% to 0.89 in 2024, then increased by 0.47% to 0.9 in 2025.
- Business Quant data shows Equity Ratio for CMPX at 0.9 in Q4 2025, 0.91 in Q3 2025, and 0.8 in Q2 2025.